AR099385A1 - Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona - Google Patents
Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-dionaInfo
- Publication number
- AR099385A1 AR099385A1 ARP150100093A ARP150100093A AR099385A1 AR 099385 A1 AR099385 A1 AR 099385A1 AR P150100093 A ARP150100093 A AR P150100093A AR P150100093 A ARP150100093 A AR P150100093A AR 099385 A1 AR099385 A1 AR 099385A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- quinazolin
- oxo
- amino
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan en la presente memoria composiciones farmacéuticas y formas de dosificación unitarias individuales de 3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidina-2,6-diona, o un estereoisómero, profármaco, sal, solvato, hidrato o clatrato aceptable para uso farmacéutico. También se proporcionan métodos para el tratamiento, control o prevención de diversos trastornos, tales como un cáncer, una enfermedad inflamatoria y/o un trastorno inmunológico. Reivindicación 1: Una forma de dosificación oral en la forma de una cápsula que comprende: 1) el Compuesto A en una cantidad de aproximadamente 0,5 a aproximadamente 3 por ciento en peso del peso total de la composición; 2) un ligante o relleno en una cantidad de aproximadamente 90 a 96 por ciento en peso del peso total de la composición, en la que el ligante o relleno es lactosa, celulosa microcristalina silicificada, o una mezcla de las mismas, en la que el compuesto A es 3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidina-2,6-diona. Reivindicación 2: La forma de dosificación oral de la reivindicación 1, que además comprende un disgregante en una cantidad de aproximadamente 1 a 5 por ciento en peso del peso total de la composición. Reivindicación 3: La forma de dosificación oral de la reivindicación 2, en la que el disgregante es croscarmelosa de sodio. Reivindicación 5: La composición oral de la reivindicación 4, en la que el lubricante es estearato de magnesio.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461927895P | 2014-01-15 | 2014-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR099385A1 true AR099385A1 (es) | 2016-07-20 |
Family
ID=52444635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150100093A AR099385A1 (es) | 2014-01-15 | 2015-01-14 | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona |
Country Status (4)
Country | Link |
---|---|
US (1) | US20150196562A1 (es) |
AR (1) | AR099385A1 (es) |
TW (1) | TW201540323A (es) |
WO (1) | WO2015108889A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS52349B (en) | 2006-09-26 | 2012-12-31 | Celgene Corporation | 5-SUBSTITUTED HINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS |
CA2829570C (en) | 2011-03-11 | 2019-05-07 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
CN104755472A (zh) | 2012-09-04 | 2015-07-01 | 细胞基因公司 | 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮的同位素体及其制备方法 |
BR112017028530A2 (pt) | 2015-07-02 | 2018-08-28 | Celgene Corp | terapia combinada para tratamento de cânceres hematológicos e tumores sólidos |
MX2018002487A (es) * | 2015-08-27 | 2018-06-15 | Celgene Corp | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinalozin-3-il)-pipe ridin-2,6-diona. |
EA201891289A1 (ru) | 2015-12-02 | 2018-11-30 | Селджин Корпорейшн | Циклическая терапия с применением 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона |
MX2019015886A (es) * | 2017-06-30 | 2020-09-10 | Celgene Corp | Composiciones y metodos de uso de 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-0xoisoindolin-5-il)metil)-2,2-difluoroacetamid a. |
KR20200105662A (ko) * | 2018-01-02 | 2020-09-08 | 셀진 코포레이션 | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 동위 이성질체 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
WO2003041326A2 (en) | 2001-11-09 | 2003-05-15 | Matsushita Electric Industrial Co., Ltd. | Moving picture coding method and apparatus |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
ZA200607799B (en) | 2004-03-22 | 2008-06-25 | Celgene Corp | Methods of using and compositions comprising immuno-modulatory compounds for the treatment and management of skin diseases or disorders |
WO2005105088A2 (en) | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
CN101098694A (zh) | 2004-11-12 | 2008-01-02 | 细胞基因公司 | 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物 |
US20060122228A1 (en) | 2004-11-23 | 2006-06-08 | Zeldis Jerome B | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
RS52349B (en) | 2006-09-26 | 2012-12-31 | Celgene Corporation | 5-SUBSTITUTED HINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS |
CN103561743A (zh) * | 2011-03-11 | 2014-02-05 | 细胞基因公司 | 利用3-(5-氨基-2-甲基-4-氧-4h-喹唑啉-3-基)-哌啶-2,6-二酮治疗癌症的方法 |
CA2829570C (en) * | 2011-03-11 | 2019-05-07 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
WO2014110558A1 (en) * | 2013-01-14 | 2014-07-17 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
-
2015
- 2015-01-14 TW TW104101235A patent/TW201540323A/zh unknown
- 2015-01-14 WO PCT/US2015/011280 patent/WO2015108889A1/en active Application Filing
- 2015-01-14 US US14/596,918 patent/US20150196562A1/en not_active Abandoned
- 2015-01-14 AR ARP150100093A patent/AR099385A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20150196562A1 (en) | 2015-07-16 |
WO2015108889A1 (en) | 2015-07-23 |
TW201540323A (zh) | 2015-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR099385A1 (es) | Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona | |
MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
MX2017010477A (es) | Compuestos triciclicos y usos de los mismos en medicina. | |
PE20160550A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
AR105808A1 (es) | Compuestos de amida para el tratamiento de trastornos médicos | |
DOP2016000156A (es) | Composiciones farmacã¿uticas que comprenden azd9291. | |
SA517381749B1 (ar) | صيغ من 2-(تيرت-بيوتيل أمينو)-4-((1r،3r،4r)-3-هيدروكسي-4-ميثيل سيكلو هكسيل أمينو)-بيريميدين-5-كربوكساميد | |
MY194087A (en) | Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament | |
EA201500365A1 (ru) | Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака | |
CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
CR20130693A (es) | Composición farmacéutica ortalmológica tópica que contiene regorafenib | |
JP2017061576A5 (es) | ||
UA117154C2 (uk) | Антагоністи s1p3 | |
CO2017011020A2 (es) | Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k) | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
CR20150327A (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
MX2015015681A (es) | Composicion farmaceutica que comprende fingolimod. | |
BR112018003335A2 (pt) | composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona | |
TN2015000524A1 (en) | Pharmaceutical compositions | |
BR112019006588A2 (pt) | composição farmacêutica de liberação imediata | |
MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
BR112018072371A2 (pt) | uso de manitol, composição farmacêutica ou uso, método para preparar uma forma de dosagem sólida compreendendo tibolona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |